USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

Key Terms

adjusted ebitda financial

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

adjusted diluted eps financial

Adjusted diluted EPS is a company’s profit per share after adding back or removing one-time items (like restructuring costs or gains) and dividing by the number of shares including potential shares from options and convertible securities. Investors use it as a cleaner view of ongoing earnings—like looking at a car’s regular fuel efficiency rather than a trip boosted by downhill coasting—to judge underlying performance and compare companies without temporary distortions.

non-gaap financial measures financial

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

ebitda financial

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It measures a company's profitability by focusing on the money it makes from its core operations, ignoring expenses like taxes and accounting adjustments. Investors use EBITDA to compare how well different companies are performing financially, as it provides a clearer picture of operational success without the influence of financial structure or accounting choices.

gaap financial

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

restricted stock units financial

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended January 3, 2026.

Key Financial and Operating Results

	Q4 2025		Q4 2024		FY 2025		FY 2024
Net sales	$226.2		$213.6		$925.3		$854.5
Net (loss) earnings*	$-1.8		$4.5		$10.8		$42.0
Diluted EPS	$-0.10		$0.23		$0.58		$2.19
Adjusted diluted EPS(1)	$0.60		$0.64		$1.93		$2.59
Adjusted EBITDA(2)	$27.3		$25.5		$101.3		$110.3
USANA Active Customers	387,000		454,000		387,000		454,000
Hiya Active Monthly Subscribers	181,700		N/A		181,700		N/A

*Pretax earnings for Q4 2025 totaled $4.0 million with income tax expense of $5.8 million. The adjustment to income taxes during the period, largely as a result of one-time impairment and cost realignment charges, is about $3.1 million greater than what would have been expected using the previously expected 65% tax rate.

Net sales, Net (loss) earnings and Adjusted EBITDA figures in millions.

Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.

Fiscal Year 2026 Outlook

• Consolidated net sales between $925 million and $1.0 billion, or flat to 8% growth.
• Net earnings between $20.3 million and $26.6 million.
• Diluted EPS between $1.11 and $1.45.
• Adjusted Diluted EPS⁽¹⁾ between $1.95 and $2.29.
• Adjusted EBITDA⁽²⁾ between $101.3 million and $109.3 million.

Q4 2025 Financial Performance

Consolidated Results
		Year-Over-Year	Sequentially
Net sales	$226 million	+6% *	+6% *
Net (loss)	-$1.8 million	N/A	N/A
Diluted EPS	-$0.10	N/A	N/A
Adjusted diluted EPS(1)	$0.60	-6%	N/A
Adjusted EBITDA(2)	$27.0 million	+7%	+98%

*No meaningful FX impact

Net (loss) earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA.

“USANA delivered fourth quarter net sales in line with our preliminary results announced on January 12, 2026,” said Kevin Guest, Chairman and Chief Executive Officer. “We began to see signs of stabilization in active customer counts in our core nutritional business as net sales in this segment increased modestly sequentially, led by growth in key markets including mainland China, the United States and Canada. Meanwhile, our omnichannel brands, Hiya and Rise, posted solid year-over-year growth.”

Fiscal Year 2025 Financial Performance

Consolidated Results
Net sales	$925 million	+8% YOY
		+9% constant currency
		-$3 million YOY FX impact
Net earnings	$10.8 million	-74%
Diluted EPS	$0.58	-74%
Adjusted diluted EPS(1)	$1.93	-25%
Adjusted EBITDA(2)	$101.3 million	-8%

Net earnings, EPS and Adjusted EBITDA figures represent amounts attributable to USANA

Mr. Guest continued, “Fiscal 2025 net sales grew 8%, driven primarily by a full-year contribution from Hiya. Net sales in the core nutritional business declined 8%, reflecting a challenging environment for customer acquisition in key markets. Despite this challenge, we continued to execute our diversification strategy towards an omnichannel model. That strategy is designed to support growth beyond our core nutritional business as well as to restructure and modernize our business for today’s evolving marketplace. Rise Wellness generated strong momentum with sales tripling, albeit off a small base in 2024, as distribution expanded into key retail outlets. The business is on pace for a robust year of sales growth supported by the launch of Protein Pop at a large club retailer in the first quarter. Net sales outside of our core nutritional business represented 16% of consolidated net sales in 2025, up from approximately 1% in 2024. We expect this share to increase to more than 20% of consolidated net sales in fiscal 2026.”

Q4 2025 Core Nutritional Business Regional Results:

Asia Pacific Region
			Year-Over-Year	Year-over-Year (Constant Currency)	Sequentially
Net sales		$151 million	-10%	No material FX impact	+8%
USANA Active Customers		306,000	-15%	N/A	-1%

Asia Pacific Sub-Regions
			Year-Over-Year	Year-over-Year (Constant Currency)	Sequentially
Greater China	Net sales	$100 million	-11%	No material FX impact	+8%
	USANA Active	208,000	-15%	N/A	-1%
	Customers
North Asia	Net sales	$17 million	+2%	+5%	-5%
	USANA Active	35,000	-8%	N/A	-5%
	Customers
Southeast Asia Pacific	Net sales	$34 million	-10%	-12%	+17%
	USANA Active	63,000	-18%	N/A	+3%
	Customers

Americas and Europe Region
			Year-Over-Year	Year-over-Year (Constant Currency)	Sequentially
Net sales*		$45 million	+1%	Flat	+4%
USANA Active Customers		81,000	-13%	N/A	+1%

*Includes $4.5 million of ‘Other’

Q4 2025 Hiya Direct to Consumer Results:

Hiya
Net sales	$30 million
Active Monthly Subscribers	181,700

Balance Sheet

The Company ended the year with $158 million in cash and cash equivalents and $14 million of debt. As of January 3, 2026, inventory totaled $107 million, an increase of approximately $35 million, or 48% compared to balances at year-end 2024. This increase was primarily driven by the addition of inventory to support the rapid growth of the Rise Wellness brands and a planned ramp up of raw materials inventory as part of bringing the production of Hiya products in-house. Importantly, our balance sheet remains in a strong net cash position, providing us with the financial flexibility to continue executing our strategic priorities.

The Company repurchased 927,000 shares in fiscal 2025 for an investment of $28 million. As of January 3, 2026, the Company had approximately $34 million remaining under the current share repurchase authorization.

Fiscal Year 2026 Outlook

Mr. Guest continued, “We are leveraging our strong foundation in the nutrition business and expanding beyond our legacy channel to connect with a greater number of health-conscious consumers worldwide. We see an extraordinary opportunity in a growing global health and wellness market to strengthen our brand relevance through an omnichannel approach. By deepening consumer engagement, empowering our Brand Partners, and executing with discipline, we believe we can accelerate profitable growth, extend our competitive advantages, and deliver sustainable long-term value for our shareholders.

“We also remain focused on product innovation and development to meet the evolving nutritional needs of our consumers. We introduced several new products and upgraded several top-selling products in 2025, and plan to launch these products across all markets in 2026. Furthermore, we intend to accelerate our technology initiatives to modernize our core systems and fundamentally improve how customers experience our brand while driving future cost efficiencies across our IT infrastructure. We are planning to strategically leverage best-in-class third-party platforms to move faster, scale smarter, and deliver capabilities to enable future growth and improve customer interactions. Our focus is on deploying the most effective technologies and partnering with industry-leading providers to create real value for customers and a durable advantage for our business. As I have recently resumed the CEO role, this plan is still being finalized and is not reflected in our fiscal 2026 guidance, and we will provide an update upon its full formalization and approval.

“Hiya is expected to deliver solid top line growth in 2026, driven by continued strength in its core direct-to-consumer business and early expansion into new distribution channels and international markets. Moreover, we have begun manufacturing Hiya products in‑house, a strategic shift that we expect will generate savings in the back half of 2026 as efficiencies scale and integration benefits materialize.

“Building on the strong momentum over the last several quarters, Rise Wellness is expected to accelerate net sales growth in 2026. Notably, Rise Wellness consists of two brands, Rise Bar and Protein Pop – a new product line we launched mid-year 2025. While Rise Bar sales were driven by entrance into a large club retailer in 2025, Protein Pop went from concept to launch on the shelves of a key retailer over a few short months. Much of the growth in Rise Wellness is expected to be driven by expansion of Protein Pop into the club retail channel.”

The Company is providing its outlook for fiscal year 2026, as detailed in the table below:

Fiscal Year 2026 Outlook
	Range
Core nutritional business net sales	$720 to $765 million*
Hiya net sales	$140 to $155 million
Rise Wellness net sales	$65 to $80 million
Consolidated net sales	$925 million to $1.0 billion
Net earnings	$20.3 million to $26.6 million
Diluted EPS	$1.11 to $1.45
Adjusted diluted EPS(1)	$1.95 to $2.29
Adjusted EBITDA(2)	$101.3 million to $109.3 million

*Reflects an expected favorable currency exchange rate impact of approximately $19 million, or 3% on net sales and one less week of operations compared to fiscal year 2025 which was a 53-week year.

Doug Hekking, Chief Financial Officer, said, “Fourth‑quarter and full‑year net sales came in modestly ahead of our expectations, although reported GAAP results reflected the impact of two notable items. During the quarter, we recorded a non‑cash impairment charge of $7.0 million of goodwill and intangibles in one of our reporting units, that resulted from a sustained decline in our share price and resulting market capitalization. We also incurred a $6.5 million charge related to our previously communicated cost realignment initiatives, primarily aligning headcount with sales levels. As a result of the impact of the impairment and cost realignment initiatives, the annualized effective income tax rate in the fourth quarter increased from 65.0% to 72.4%. The adjustment was approximately $3.1 million greater than what would have been expected using the previously expected 65.0% tax rate. The fourth quarter also included incremental net sales of approximately $11.2 million attributable to the additional week of operations in the core nutritional business.

“Looking ahead, we are projecting fiscal 2026 consolidated net sales in a range of flat to 8% growth. Our outlook for the core nutritional business anticipates an approximately 0-5% decline in fiscal 2026, but we remain confident that the actions underway will stabilize the business over time and ultimately position it to return to sustainable growth. Hiya is anticipated to grow net sales 6% to 17%, while Rise Wellness is expected to continue to deliver accelerated net sales growth.

“We are making meaningful investments in inventory, working capital, and capital expenditures, while simultaneously deploying incremental operational resources to support the growth of Hiya and Rise Wellness including building brand awareness. These actions are designed to strengthen the scalability of both platforms and position the brands for sustained, long-term value creation.”

____________________
(1)		Adjusted Diluted EPS is a non-GAAP financial measure. The Company excludes cost realignment expenses, impairment expense, gain on sale of assets, and acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted EPS. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted EPS (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.
(2)		Adjusted EBITDA is a non-GAAP financial measure. Please refer to “Non-GAAP Financial Measures” and “Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)” in this press release for an explanation and reconciliation of this non-GAAP financial measure.

Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, transaction-related expenses and integration costs for the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

Adjusted diluted EPS (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, integration costs related to the Hiya acquisition, cost realignment expenses, impairment expense, and gain on sale of assets.

Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted EPS (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”) and investors should not directly compare with or infer relationship from any of the Company’s operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted EPS. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

Reconciliation of Net (Loss) Earnings (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands)
		Quarter Ended								Year Ended
		January 3, 2026				December 28, 2024				January 3, 2026				December 28, 2024
Net (loss) earnings attributable to USANA (GAAP)		$	(1,775	)		$	4,454			$	10,760			$	42,030
Net earnings attributable to noncontrolling interest			180				30				717				30
Net (loss) earnings		$	(1,595	)		$	4,484			$	11,477			$	42,060
Adjustments:
Income taxes		$	5,772			$	5,945			$	30,050			$	34,291
Interest (income) expense			(372	)			(2,609	)			(1,573	)			(11,038	)
Depreciation and amortization			5,488				5,590				21,538				21,935
Amortization of intangible assets - Hiya			4,798				294				18,164				294
Earnings before interest, taxes, depreciation, and amortization (EBITDA)		$	14,091			$	13,704			$	79,656			$	87,542
Add EBITDA adjustments:
Non-cash share-based compensation			3,750				3,613				13,828				14,558
Transaction, integration and transition costs - Hiya			443				8,243				1,314				8,243
Inventory step-up - Hiya			—				38				1,126				38
Cost realignment			6,463				—				6,463				—
Impairment			6,967				—				6,967				—
Gain on disposal of assets			(3,240	)			—				(3,240	)			—
Consolidated adjusted EBITDA			28,474				25,598				106,114				110,381
Less: Adjusted EBITDA attributable to noncontrolling interest			(1,195	)			(101	)			(4,799	)			(101	)
Adjusted EBITDA attributable to USANA		$	27,279			$	25,497			$	101,315			$	110,280

Reconciliation of Diluted (Loss) Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP) (in thousands, except per share data)
		Quarter Ended								Year Ended
		January 3, 2026				December 28, 2024				January 3, 2026				December 28, 2024
Net (loss) earnings attributable to USANA (GAAP)		$	(1,775	)		$	4,454			$	10,760			$	42,030
(Loss) earnings per common share - Diluted (GAAP)		$	(0.10	)		$	0.23			$	0.58			$	2.19
Weighted Average common shares outstanding - Diluted			18,302				19,104				18,574				19,162
Adjustment to net (loss) earnings:
Transaction, integration and transition costs - Hiya		$	443			$	8,243			$	1,314			$	8,243
Inventory step-up - Hiya			—				38				1,126				38
Cost realignment			6,463				—				6,463				—
Impairment			6,967				—				6,967				—
Gain on disposal of assets			(3,240	)			—				(3,240	)			—
Amortization of intangible assets - Hiya			4,798				294				18,164				294
Adjustments to net (loss) earnings attributable to noncontrolling interest			(1,015	)			(70	)			(4,081	)			(70	)
Income tax effect of adjustments to net earnings (loss)			(1,658	)			(823	)			(1,662	)			(823	)
Adjusted net earnings attributable to USANA		$	10,983			$	12,136			$	35,811			$	49,712
Adjusted earnings per common share - Diluted		$	0.60			$	0.64			$	1.93			$	2.59
Weighted average common shares outstanding - Diluted			18,302				19,104				18,574				19,162

Management Commentary Document and Conference Call

For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, February 18, 2026 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “expect,” “enhance,” “drive,” “anticipate,” “intend,” “improve,” “promote,” “should,” “believe,” “continue,” “plan,” “goal,” “opportunity,” “estimate,” “predict,” “may,” “will,” “could,” and “would,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding growth for Hiya and Rise Wellness in 2026 and continued growth in the future; statements about the Company’s long-term growth; and the statements under the sub-heading “Fiscal Year 2026 Outlook.” Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Brand Partners; risk that our Brand Partner compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to Hiya’s ability to adapt to changes in the digital marketing environment to continue to generate customer acquisition, including changes in social media advertising algorithms; risks related to Rise Wellness’ dependence on product orders from certain key retailers – specifically, if future orders from those retailers do not meet our forecasts; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with our operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that Hiya and Rise Wellness disrupt the Company’s overall strategic plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability to retain key personnel of Hiya and Rise Wellness; the ability to realize the benefits of the Hiya acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya’s business with USANA’s business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com. More information on Rise Wellness can be found on www.risebar.com.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data)
		Quarter Ended								Year Ended
		January 3, 2026				December 28, 2024				January 3, 2026				December 28, 2024
Net sales		$	226,200			$	213,613			$	925,257			$	854,503
Cost of sales			49,408				38,553				200,852				161,212
Gross profit			176,792				175,060				724,405				693,291
Operating expenses:
Brand Partner incentives			81,462				93,502				336,171				363,699
Selling, general and administrative			78,081				73,348				337,372				263,268
Cost realignment and impairment			13,430				—				13,430				—
Total operating expenses			172,973				166,850				686,973				626,967
Earnings from operations			3,819				8,210				37,432				66,324
Other income (expense):
Interest income			495				2,738				2,415				11,319
Interest expense			(123	)			(129	)			(842	)			(281	)
Other, net			(14	)			(390	)			2,522				(1,011	)
Other income (expense), net			358				2,219				4,095				10,027
Earnings before income taxes			4,177				10,429				41,527				76,351
Income taxes			5,772				5,945				30,050				34,291
Net (loss) earnings			(1,595	)			4,484				11,477				42,060
Less: Net (loss) earnings attributable to redeemable noncontrolling interest			(180	)			(30	)			(717	)			(30	)
Net (loss) earnings attributable to USANA		$	(1,775	)		$	4,454			$	10,760			$	42,030
(Loss) earnings per common share attributable to USANA
(Loss) earnings per share - diluted		$	(0.10	)		$	0.23			$	0.58			$	2.19
Weighted average shares outstanding - diluted			18,302				19,104				18,574				19,162

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)
	As of January 3, 2026			As of December 28, 2024
ASSETS
Current assets
Cash and cash equivalents	$	158,380		$	181,768
Inventories		102,608			69,735
Prepaid expenses and other current assets		27,417			27,684
Total current assets		288,405			279,187
Property and equipment, net		94,383			94,565
Goodwill		137,962			144,168
Intangible assets, net		133,151			151,823
Deferred tax assets		27,209			19,644
Other assets*		61,805			58,806
Total assets	$	742,915		$	748,193
LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable	$	17,263		$	11,984
Line of credit		14,000			23,000
Other current liabilities		97,302			104,641
Total current liabilities		128,565			139,625
Deferred tax liabilities		4,892			4,073
Other long-term liabilities		23,186			18,163
Total liabilities		156,643			161,861
Redeemable noncontrolling interest		53,168			54,223
Total stockholders' equity attributable to USANA		533,104			532,109
Total liabilities, redeemable noncontrolling interest, and stockholders' equity	$	742,915		$	748,193

*Includes noncurrent inventories of $4,799 and $2,688 as of 03-Jan-26 and 28-Dec-24, respectively. Total inventories were $107,407 and $72,423 as of 03-Jan-26 and 28-Dec-24, respectively.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES SALES BY REGION (in thousands) (unaudited)
	Quarter Ended
	January 3, 2026						December 28, 2024						Change from prior year				Percent change			Currency impact on sales				Percent change excluding currency impact
Core nutritional:
Asia Pacific
Greater China	$	100,053		44.2	%		$	112,587		52.7	%		$	(12,534	)		(11.1	)%		$	1,332			(12.3	)%
Southeast Asia Pacific		34,211		15.1	%			38,061		17.8	%			(3,850	)		(10.1	)%			592			(11.7	)%
North Asia		16,830		7.5	%			16,542		7.8	%			288			1.7	%			(614	)		5.5	%
Asia Pacific total		151,094		66.8	%			167,190		78.3	%			(16,096	)		(9.6	)%			1,310			(10.4	)%
Americas and Europe		40,494		17.9	%			42,776		20.0	%			(2,282	)		(5.3	)%			619			(6.8	)%
Core nutritional total		191,588		84.7	%			209,966		98.3	%			(18,378	)		(8.8	)%			1,929			(9.7	)%
Hiya(1)		30,105		13.3	%			1,970		0.9	%			28,135			N/A				—			N/A
Other		4,507		2.0	%			1,677		0.8	%			2,830			168.8	%			—			168.8	%
Consolidated total	$	226,200		100.0	%		$	213,613		100.0	%		$	12,587			5.9	%		$	1,929			5.0	%

______________________________
(1)		Percentage change for Hiya is not applicable due to timing of the acquisition.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CORE NUTRITIONAL BUSINESS ACTIVE BRAND PARTNERS AND ACTIVE PREFERRED CUSTOMERS BY REGION (unaudited)
Core Nutritional Business Active Brand Partners by Region(1)
		As of January 3, 2026					As of December 28, 2024
Asia Pacific
Greater China		61,000		35.1	%		67,000		35.4	%
Southeast Asia Pacific		46,000		26.4	%		51,000		27.0	%
North Asia		27,000		15.5	%		26,000		13.8	%
Asia Pacific Total		134,000		77.0	%		144,000		76.2	%
Americas and Europe		40,000		23.0	%		45,000		23.8	%
		174,000		100.0	%		189,000		100.0	%
Core Nutritional Business Active Preferred Customers by Region(2)
		As of January 3, 2026					As of December 28, 2024
Asia Pacific
Greater China		147,000		69.0	%		179,000		67.6	%
Southeast Asia Pacific		17,000		8.0	%		26,000		9.8	%
North Asia		8,000		3.8	%		12,000		4.5	%
Asia Pacific Total		172,000		80.8	%		217,000		81.9	%
Americas and Europe		41,000		19.2	%		48,000		18.1	%
		213,000		100.0	%		265,000		100.0	%

______________________________
(1)		Brand Partners are independent distributors of our products who also purchase our products for their personal use. We only count as active those Brand Partners who have purchased from us any time during the most recent three-month period, either for personal use or resale.
(2)		Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES OPERATING RESULTS AS A PERCENTAGE OF NET SALES (unaudited)
		Quarter Ended
		January 3, 2026									December 28, 2024
		Core nutritional & other			Hiya direct- to-consumer			Consolidated			Core nutritional & other			Hiya direct- to-consumer			Consolidated
Net sales		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%
Cost of sales		20.6	%		29.9	%		21.8	%		17.9	%		30.4	%		18.0	%
Gross profit		79.4	%		70.1	%		78.2	%		82.1	%		69.6	%		82.0	%
Operating expenses:
Brand Partner incentives		41.5	%		—	%		36.0	%		44.2	%		—	%		43.8	%
Selling, general and administrative		29.5	%		67.2	%		34.5	%		34.1	%		62.2	%		34.3	%
Cost realignment and impairment		6.8	%		—	%		5.9	%		—	%		—	%		—	%
Total operating expenses		77.8	%		67.2	%		76.4	%		78.3	%		62.2	%		78.1	%
Earnings from operations		1.6	%		2.9	%		1.8	%		3.8	%		7.4	%		3.9	%
Amortization of acquired intangible assets		0.1	%		15.9	%		2.3	%		0.1	%		14.9	%		0.2	%
		Year Ended
		January 3, 2026									December 28, 2024
		Core nutritional & other			Hiya direct- to-consumer			Consolidated			Core nutritional & other			Hiya direct- to-consumer			Consolidated
Net sales		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%
Cost of sales		19.5	%		35.1	%		21.7	%		18.8	%		30.4	%		18.9	%
Gross profit		80.5	%		64.9	%		78.3	%		81.2	%		69.6	%		81.1	%
Operating expenses:
Brand Partner incentives		42.4	%		—	%		36.3	%		42.7	%		—	%		42.6	%
Selling, general and administrative		32.2	%		62.3	%		36.5	%		30.7	%		62.2	%		30.8	%
Cost realignment and impairment		1.7	%		—	%		1.5	%		—	%		—	%		—	%
Total operating expenses		76.3	%		62.3	%		74.3	%		73.4	%		62.2	%		73.4	%
Earnings from operations		4.2	%		2.6	%		4.0	%		7.8	%		7.4	%		7.7	%
Amortization of acquired intangible assets		0.2	%		13.8	%		2.1	%		0.1	%		14.9	%		0.2	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260217081610/en/

Investor contact:

Andrew Masuda

Investor Relations

(801) 954-7201

investor.relations@usanainc.com

Media contact:

Sarah Searle

(801) 954-7626

media@usanainc.com

Source: USANA Health Sciences, Inc.